Peptides for muscle growth and performance: what human evidence shows
Why growth-hormone signals, mitochondrial biology, and body-composition claims do not automatically prove more muscle, strength, recovery, or performance.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
The quick overview
Muscle and performance marketing often treats a rise in growth hormone, IGF-1, or a mitochondrial marker as if it were proven muscle gain or better athletic function. Those are different endpoints.
GHRP-2, CJC-1295, and ipamorelin can affect hormone signaling but are not FDA approved for muscle growth. Tesamorelin's approval is limited to excess abdominal fat in adults with HIV and lipodystrophy. MOTS-c remains largely preclinical, while elamipretide has a narrow Barth syndrome muscle-strength indication.
Side-by-side comparison
| Peptide | Status | Evidence | Studied for |
|---|---|---|---|
| GHRP-2 | Not FDA approved | Early human evidence | Growth-hormone release; Appetite and food intake; Endocrine testing and physiology |
| CJC-1295 | Not FDA approved | Early human evidence | Growth hormone and IGF-1 levels; Pharmacology and tolerability |
| Ipamorelin | Not FDA approved | Early human evidence | Growth hormone release; Gastrointestinal motility; Postoperative ileus |
| Tesamorelin | FDA approved for specific uses | Strong human evidence for approved uses | HIV-associated lipodystrophy; Visceral abdominal fat; Metabolic measures |
| MOTS-c | Preclinical research | Mostly animal or lab research | Insulin sensitivity and metabolic regulation in animal models; Exercise adaptation and physical capacity; Age-related metabolic decline |
| Elamipretide | FDA approved for specific uses | Moderate human evidence | Barth syndrome; Primary mitochondrial myopathy; Mitochondrial function and muscle energetics |
Studied for
Growth-hormone release · Appetite and food intake · Endocrine testing and physiology
Studied for
Growth hormone and IGF-1 levels · Pharmacology and tolerability
Studied for
Growth hormone release · Gastrointestinal motility · Postoperative ileus
Studied for
HIV-associated lipodystrophy · Visceral abdominal fat · Metabolic measures
Studied for
Insulin sensitivity and metabolic regulation in animal models · Exercise adaptation and physical capacity · Age-related metabolic decline
Studied for
Barth syndrome · Primary mitochondrial myopathy · Mitochondrial function and muscle energetics
Approved versus investigational
An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.
What researchers are studying
- Growth hormone and IGF-1 signaling
- Body composition in narrowly defined medical populations
- Mitochondrial muscle energetics
- Strength, recovery, and physical-function outcomes
Risks and reasons for caution
- Hormone release and biomarker changes are not validated muscle, strength, or performance outcomes.
- Narrow rare-disease or HIV-lipodystrophy approvals do not validate use in healthy athletes or for bodybuilding.
- FDA identifies significant evidence and safety gaps for compounded GHRP-2, CJC-1295, ipamorelin, and MOTS-c.
What remains uncertain
- Whether the unapproved peptides produce meaningful strength or function gains
- Long-term endocrine, glucose, cardiovascular, immune, and product-quality risks
- Safety and effects of combinations promoted online
Questions to ask a healthcare professional
1. Did the study measure muscle mass, strength, function, or only a hormone level?
2. Was the population healthy, injured, critically ill, or living with a rare disease?
3. Is the exact product approved for this use?
4. Were benefits large enough to matter and accompanied by adequate safety follow-up?
Plain-English takeaway
The strongest muscle claims usually rest on the weakest substitution: hormone or mitochondrial signaling standing in for actual strength and function. No unapproved peptide in this group has established a safe bodybuilding or performance indication.
References
- 1FDA: selected compounded-peptide safety risks
FDA evidence gaps and potential risks for GHRP-2, CJC-1295, ipamorelin, and MOTS-c.
- 2GHRP-2 hormone and appetite study
Small physiology study that did not test muscle growth or performance.
- 3FDA prescribing information: Egrifta SV
Narrow tesamorelin indication and explicit limits on general weight-management claims.
- 4MMPOWER-3 randomized trial
Phase 3 mitochondrial myopathy trial that did not meet walking-distance or fatigue endpoints.